These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17049298)

  • 1. Building oligonucleotide therapeutics using non-natural chemistries.
    Wilson C; Keefe AD
    Curr Opin Chem Biol; 2006 Dec; 10(6):607-14. PubMed ID: 17049298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SELEX with modified nucleotides.
    Keefe AD; Cload ST
    Curr Opin Chem Biol; 2008 Aug; 12(4):448-56. PubMed ID: 18644461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sugar boost: when ribose modifications improve oligonucleotide performance.
    Faria M; Ulrich H
    Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligonucleotide charge reversal: 2'-O-lysylaminohexyl modified oligonucleotides.
    Winkler J; Noe CR
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):939-42. PubMed ID: 18058513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of antisense oligonucleotides comprising 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA): specificity, potency, and duration of activity.
    Ferrari N; Bergeron D; Tedeschi AL; Mangos MM; Paquet L; Renzi PM; Damha MJ
    Ann N Y Acad Sci; 2006 Oct; 1082():91-102. PubMed ID: 17145930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense treatments for biothreat agents.
    Warfield KL; Panchal RG; Aman MJ; Bavari S
    Curr Opin Mol Ther; 2006 Apr; 8(2):93-103. PubMed ID: 16610760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokines and therapeutic oligonucleotides.
    Hartmann G; Bidlingmaier M; Eigler A; Hacker U; Endres S
    Cytokines Cell Mol Ther; 1997 Dec; 3(4):247-56. PubMed ID: 9740353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2'-O-Lysylaminohexyl oligonucleotides: modifications for antisense and siRNA.
    Winkler J; Gilbert M; Kocourková A; Stessl M; Noe CR
    ChemMedChem; 2008 Jan; 3(1):102-10. PubMed ID: 17979170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development and future of oligonucleotide-based therapies for cervical cancer.
    Gu W; Putral LN; Irving A; McMillan NA
    Curr Opin Mol Ther; 2007 Apr; 9(2):126-31. PubMed ID: 17458165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotides.
    Prakash TP; Kawasaki AM; Wancewicz EV; Shen L; Monia BP; Ross BS; Bhat B; Manoharan M
    J Med Chem; 2008 May; 51(9):2766-76. PubMed ID: 18399648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligonucleotide analogues: an overview.
    Matteucci M
    Ciba Found Symp; 1997; 209():5-14; discussion 14-8. PubMed ID: 9383565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of target validation and the impact of oligonucleotides.
    Jones SW; Lindsay MA
    Curr Opin Mol Ther; 2004 Oct; 6(5):546-50. PubMed ID: 15537056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Oligonucleotide therapeutics - an emerging novel class of compounds].
    Wacheck V
    Wien Med Wochenschr; 2006 Sep; 156(17-18):481-7. PubMed ID: 17041803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease.
    Séguin RM; Ferrari N
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1505-17. PubMed ID: 19715448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of side reactions during the annealing of small interfering RNAs.
    Seiffert S; Debelak H; Hadwiger P; Jahn-Hofmann K; Roehl I; Vornlocher HP; Noll B
    Anal Biochem; 2011 Jul; 414(1):47-57. PubMed ID: 21376008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modified 2',4'-carbocyclic-LNAs and -ENAs leads to significant modulation of antisense properties.
    Zhou C; Liu Y; Andaloussi M; Badgujar N; Plashkevych O; Chattopadhyaya J
    J Org Chem; 2009 Jan; 74(1):118-34. PubMed ID: 19055352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the RNase H cleavage kinetics and blood serum stability of the north-conformationally constrained and 2'-alkoxy modified oligonucleotides.
    Honcharenko D; Barman J; Varghese OP; Chattopadhyaya J
    Biochemistry; 2007 May; 46(19):5635-46. PubMed ID: 17411072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic oligonucleotides: the state-of-the-art in purification technologies.
    Sanghvi YS; Schulte M
    Curr Opin Drug Discov Devel; 2004 Nov; 7(6):765-76. PubMed ID: 15595437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the medicinal chemistry of antisense oligonucleotides.
    Uhlmann E
    Curr Opin Drug Discov Devel; 2000 Mar; 3(2):203-13. PubMed ID: 19649851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strand-specific silencing of a picornavirus by RNA interference: evidence for the superiority of plus-strand specific siRNAs.
    Schubert S; Rothe D; Werk D; Grunert HP; Zeichhardt H; Erdmann VA; Kurreck J
    Antiviral Res; 2007 Mar; 73(3):197-205. PubMed ID: 17112603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.